GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS
- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the third quarter 2026.
“Gilead delivered an exceptional third quarter, with our strongest year-over- year base business growth in more than a decade, reflecting the strength, breadth and durability of our business,” said Daniel O’Day, Gilead’s Chairman and Chief Executive Officer. “Our performance enabled us to raise our full year base business revenue guidance again this quarter, bringing the total increase to $1.6 billion since the start of 2026. Our HIV business grew 18% and HIV prevention sales nearly doubled year-over-year. With multiple ongoing and potential launches across HIV and Oncology, important progress in Inflammation and a disciplined operating model, Gilead is well positioned for business growth and impact for patients.”
• Total third quarter 2026 product sales increased 13% to $8.3 billion compared to the same period in 2025, primarily driven by higher sales of HIV products, Trodelvy® (sacituzumab govitecan-hziy) and Livdelzi® (seladelpar), partially offset by lower sales of Veklury® (remdesivir) and Cell Therapy products. Higher product sales were partially offset by lower royalty, contract and other revenues, primarily driven by revenues recognized in the prior year related to a previous sale of intellectual property, which did not repeat in the current year.
• Diluted earnings per share (“EPS”) was $1.94 in the third quarter 2026 compared to $2.43 in the same period in 2025. The decrease was primarily driven by net losses from equity securities in the current year compared to net gains in the prior year, higher operating expenses, higher income tax expense and lower royalty, contract and other revenues, partially offset by higher product sales and lower acquired in-process research and development (“IPR&D”) expenses.
• Non-GAAP diluted EPS was $2.55 in the third quarter 2026 compared to $2.47 in the same period in 2025. The increase was primarily driven by higher product sales and lower acquired IPR&D expenses, partially offset by higher operating expenses, higher income tax expense and lower royalty, contract and other revenues.
• As of September 30, 2026, Gilead had $6.4 billion of cash, cash equivalents and marketable debt securities compared to $10.6 billion as of December 31, 2025. The decrease was primarily driven by year-to-date cash outflows of $11.3 billion related to acquisitions, $2.8 billion of debt repayments, $3.1 billion of dividend payments and $1.1 billion of common stock repurchases, partially offset by $11.2 billion of operating cash flow and $4.1 billion of net proceeds from debt financing.
• During the third quarter 2026, Gilead generated $5.0 billion in operating cash flow.
• During the third quarter 2026, Gilead paid dividends of $1.0 billion and repurchased $370 million of common stock.
As noted in the section above, total third quarter 2026 product sales increased compared to the same period in 2025. Total third quarter 2026 product sales excluding Veklury increased 16% to $8.2 billion compared to the same period in 2025, primarily due to higher sales of HIV products, Trodelvy and Livdelzi, partially offset by lower sales of Cell Therapy products.
product sales increased 18% to $6.2 billion in the third quarter 2026 compared to the same period in 2025, primarilydriven by higher average realized price, higher demand in HIV prevention and favorable inventory dynamics.
(bictegravir 50mg/emtricitabine (“FTC”) 200mg/tenofovir alafenamide (“TAF”) 25mg) sales increased 10% to $4.1 billion in the third quarter 2026 compared to the same period in 2025, primarily driven by higher demand, higher average realized price and favorable inventory dynamics.
(FTC 200mg/TAF 25mg) sales increased 49% to $1.0 billion in the third quarter 2026 compared to the same period in 2025, primarily driven by higher average realized price and favorable inventory dynamics.
portfolio sales increased 13% to $927 million in the third quarter 2026 compared to the same period in 2025, primarily reflecting higher demand for Livdelzi, as well as higher average realized price for chronic hepatitis C virus (“HCV”) and chronic hepatitis B virus products, partially offset by lower demand for HCV products.
sales decreased 69% to $86 million in the third quarter 2026 compared to the same period in 2025, primarily driven by lower rates of COVID-19-related hospitalizations.
product sales decreased 18% to $355 million in the third quarter 2026 compared to the same period in 2025, reflecting ongoing competitive headwinds.
(sacituzumab govitecan-hziy) sales increased 42% to $506 million in the third quarter 2026 compared to the same period in 2025, primarily driven by higher demand.
Third Quarter 2026 Product Gross Margin, Operating Expenses and Effective Tax Rate
• Product gross margin was 81.0% in the third quarter 2026 compared to 78.6% in the same period in 2025. Non-GAAP product gross margin was 88.1% in the third quarter 2026 compared to 86.5% in the same period in 2025. These increases were primarily driven by the expiration of a royalty-related obligation.
• Research and development (“R&D”) expenses and non-GAAP R&D expenses increased to $1.6 billion in the third quarter 2026 compared to $1.3 billion in the same period in 2025, primarily driven by higher employee-related and clinical materials costs.
• Selling, general and administrative (“SG&A”) expenses increased to $1.6 billion in the third quarter 2026 compared to $1.4 billion in the same period in 2025, primarily driven by higher HIV promotional activities, integration costs related to our recent acquisitions, higher expenses related to legal matters and higher employee-related costs. Non-GAAP SG&A expenses increased to $1.5 billion in the third quarter 2026 compared to $1.4 billion in the same period in 2025, primarily due to higher HIV promotional activities, higher expenses related to legal matters and higher employee-related costs.
• The effective tax rate (“ETR”) was 20.7% in the third quarter 2026 compared to 16.2% in the same period in 2025, primarily driven by a settlement with a tax authority and remeasurement of certain deferred tax liabilities in the prior year, which did not repeat in the current year. The non-GAAP ETR was 19.0% in the third quarter 2026 compared to 17.5% in the same period in 2025, primarily due to the settlement with a tax authority in the prior year.
Our full year 2026 GAAP and non-GAAP diluted loss per share guidance includes the impact of approximately $9.88 due to acquired IPR&D charges of $12.4 billion related to the Arcellx, Tubulis, Ouro Medicines and PepStar transactions announced this year, net of the impact of the Lakefront collaboration and related taxes.
Additional information and a reconciliation between GAAP and non-GAAP financial information for the 2026 guidance is provided in the accompanying tables. The financial guidance is subject to a number of risks and uncertainties. See the Forward-Looking Statements section below.
• Received U.S. Food and Drug Administration (“FDA”) approval for Bixlenvo™ (bictegravir 75 mg/lenacapavir 50 mg) for the treatment of HIV in adults who are virologically suppressed on a stable antiretroviral regimen, including those switching from complex multi-tablet regimens. Bixlenvo is a complete single- tablet regimen indicated for the treatment of HIV to replace current antiretroviral regimens in people with virological suppression with no known or suspected resistance to bictegravir or lenacapavir.
• Announced the expansion of the six royalty-free voluntary licensing agreements for twice-yearly lenacapavir to include the investigational once-yearly lenacapavir for HIV prevention, if approved. This agreement covers 120 high- incidence countries and will support manufacturing readiness, technology transfer and future supply while the Phase 3 PURPOSE-365 trial is ongoing. If approved, once-yearly lenacapavir could provide a full year of HIV prevention with a single annual dose, expanding prevention choice and helping address barriers that can limit HIV pre-exposure prophylaxis (“PrEP”) uptake and persistence.
• Announced a new agreement with the Pan American Health Organization (“PAHO”) to accelerate access for twice-yearly lenacapavir for HIV prevention across all PAHO Member States in Latin America and the Caribbean. This agreement is part of Gilead’s broader global access strategy for lenacapavir which combines voluntary licensing, technology transfer, no-profit supply, regional access pathways and partnerships in providing access to HIV prevention.
• Announced European Commission (“EC”) marketing authorization for Trodelvy in combination with Keytruda® (pembrolizumab) for the treatment of adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (“mTNBC”) who have not received prior systemic therapy for metastatic disease and whose tumors express PD-L1 (CPS≥10). This decision follows the recent EC approval of Trodelvy as a monotherapy for the treatment of adults with unresectable locally advanced or mTNBC who have not received prior systemic therapy for metastatic disease and are not candidates for PD-(L)1 inhibitors. Trodelvy is now the only approved Trop-2 directed ADC and backbone therapy for 1L mTNBC across PD-L1 status.
• Announced a definitive agreement with PepStar Therapeutics Limited (“PepStar”), a privately held, clinical-stage biotechnology company, to acquire PepStar’s oral IL-23R inhibitor program. This includes lead asset HCXT-2001, an investigational, oral, macrocyclic peptide inhibitor of IL-23R, currently in Phase 1 development for immune-mediated inflammatory diseases. Closing of the transaction is subject to certain customary conditions.
• Presented new positive results from the Phase 2 SWIFT study evaluating emvistegrast, a once-daily oral alpha-4-beta-7 inhibitor, in adults with moderately-to-severely active ulcerative colitis (“UC”) at the United European Gastroenterology Week. Emvistegrast 200mg met its primary endpoint of clinical response at Week 12, with a generally well-tolerated safety profile. These findings support Gilead’s plans to initiate a Phase 3 study of emvistegrast 200mg as a monotherapy for UC in 2027. Emvistegrast is an investigational product that is not approved anywhere globally, and the safety and efficacy of its use is not yet established.
• Announced opening of new Research Center to expand capabilities in oncology, inflammation and research data science. The Research Center is the first of three projects supporting the $32 billion investment in U.S. research, development and manufacturing through 2030.
• In October 2026, the Centers for Medicare and Medicaid Services completed the process of setting the Maximum Fair Price for Biktarvy under Medicare. The new price will be effective and impact our Biktarvy revenue starting January 1, 2028.
• The Board declared a quarterly dividend of $0.82 per share of common stock for the fourth quarter of 2026. The dividend is payable on December 30, 2026, to stockholders of record at the close of business on December 15, 2026. Future dividends will be subject to Board approval.
Certain amounts and percentages in this press release may not sum or recalculate due to rounding.
At 1:30 p.m. Pacific Time today, Gilead will host a conference call to discuss Gilead’s results. A live webcast will be available on http://investors.gilead.com and will be archived on www.gilead.com for one year.
The information presented in this document has been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”), unless otherwise noted as non-GAAP. Management believes non-GAAP information is useful for investors, when considered in conjunction with Gilead’s GAAP financial information, because management uses such information internally for its operating, budgeting and financial planning purposes. Non-GAAP information is not prepared under a comprehensive set of accounting rules and should only be used to supplement an understanding of Gilead’s operating results as reported under GAAP. Non-GAAP financial information generally excludes acquisition-related expenses including amortization of acquired intangible assets, restructuring charges and other items that are considered unusual or not representative of underlying trends of Gilead’s business, fair value adjustments of equity securities, the related tax charges or benefits associated with such exclusions and other discrete tax charges or benefits not representative of underlying trends such as changes in tax laws, transfers of intangible assets between certain legal entities, and effects of legal entity restructurings. Although Gilead consistently excludes the amortization of acquired intangible assets from the non-GAAP financial information, management believes that it is important for investors to understand that such intangible assets were recorded as part of acquisitions and contribute to ongoing revenue generation. Non-GAAP measures may be defined and calculated differently by other companies in the same industry. Reconciliations of the non-GAAP financial measures to the most directly comparable GAAP financial measures are provided in the accompanying tables.
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.
Statements included in this press release that are not historical in nature are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Gilead cautions readers that forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include those relating to: Gilead’s ability to achieve its full year 2026 financial guidance and future projected financial results; impacts resulting from regulatory or legislative policies or processes, including the impact from pricing reform in the Inflation Reduction Act (such as Medicare Part D pricing reform and the Biktarvy Maximum Fair Price determination), the expiration of subsidies related to the Affordable Care Act, our most-favored-nation pricing agreement with the U.S. government and tariffs; Gilead’s ability to make progress on any of its long-term ambitions or priorities laid out in its corporate strategy; Gilead’s ability to accelerate or sustain revenues for its virology, oncology, inflammation and other programs; Gilead’s ability to manage, execute and realize the potential benefits of acquisitions, collaborations or licensing arrangements, including the announced PepStar acquisition; the risk that Gilead’s U.S. manufacturing and R&D investment may not achieve their intended benefits; patent protection and estimated loss of exclusivity for our products and product candidates; Gilead’s ability to initiate, progress or complete clinical trials within currently anticipated timeframes or at all, the possibility of unfavorable results from ongoing and additional clinical trials, including those involving anito-cel, emvistegrast, lenacapavir and HCXT-2001 (such as PURPOSE-365 and SWIFT), and the risk that safety and efficacy data from clinical trials may not warrant further development of Gilead’s product candidates or the product candidates of Gilead’s strategic partners; Gilead’s ability to resolve the issues cited by the FDA in pending clinical holds to the satisfaction of the FDA and the risk that FDA may not remove such clinical holds, in whole or in part, in a timely manner or at all; Gilead’s ability to submit new drug applications for new product candidates or expanded indications in the currently anticipated timelines; Gilead’s ability to receive or maintain regulatory approvals in a timely manner or at all, and the risk that any such approvals, if granted, may be subject to significant limitations on use and may be subject to withdrawal or other adverse actions by the applicable regulatory authority; Gilead’s ability to successfully commercialize its products; the risk of potential disruptions to the manufacturing and supply chain of Gilead’s products; pricing and reimbursement pressures from government agencies and other third parties, including required rebates and other discounts; a larger than anticipated shift in payer mix to more highly discounted payer segments; market share and price erosion caused by the introduction of generic versions of Gilead products; the risk that physicians and patients may not see advantages of Gilead’s products over other therapies, including Bixlenvo and Trodelvy; Gilead’s ability to effectively manage, execute and realize the anticipated benefits of the access strategy relating to lenacapavir for HIV PrEP, including voluntary licensing arrangements and external partnerships relating to lenacapavir; and other risks identified from time to time in Gilead’s reports filed with the SEC, including annual reports on Form 10-K, quarterly reports on Form 10-Q and current reports on Form 8-K. In addition, Gilead makes estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses and related disclosures. Gilead bases its estimates on historical experience and on various other market specific and other relevant assumptions that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. There may be other factors of which Gilead is not currently aware that may affect matters discussed in the forward-looking statements and may also cause actual results to differ significantly from these estimates. Further, results for the quarter ended September 30, 2026 are not necessarily indicative of operating results for any future periods. Gilead directs readers to its press releases, annual reports on Form 10-K, quarterly reports on Form 10-Q and other subsequent disclosure documents filed with the SEC. Gilead claims the protection of the Safe Harbor contained in the Private Securities Litigation
The reader is cautioned that forward-looking statements are not guarantees of future performance and is cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements are based on information currently available to Gilead and Gilead assumes no obligation to update or supplement any such forward-looking statements other than as required by law. Any forward-looking statements speak only as of the date hereof or as of the dates indicated in the statements.
Additional information is available on our Investor Relations website, https://investors.gilead.com. Among other things, an estimate of Acquired IPR&D expenses is expected to be made available on the Quarterly Results page within the first ten (10) days after the end of each quarter. # # # G ilead owns or has rights to various trademarks, copyrights and trade names used in its business, including the following: GILEAD®, GILEAD SCIENCES®, KITE®, AMBISOME®, ATRIPLA®, BIXLENVO ™ , BIKTARVY®, CAYSTON®, COMPLERA®, DESCOVY®, DESCOVY FOR PREP®, EMTRIVA®, EPCLUSA®, EVIPLERA®, GENVOYA®, HARVONI®, HEPCLUDEX®, JYSELECA®, LIVDELZI®/LYVDELZI®, LETAIRIS®, ODEFSEY®, SOVALDI®, STRIBILD®, SUNLENCA®, TECARTUS®, TRODELVY®, TRUVADA®, TRUVADA FOR PREP®, TYBOST®, VEKLURY®, VEMLIDY®, VIREAD®, VOSEVI®, YESCARTA®, YEZTUGO®/YEYTUO® and ZYDELIG®. Other trademarks and trade names are the property of their respective owners. For more information on Gilead Sciences, Inc., please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).
CONTACTS: Investors: Jacquie Ross, CFA [email protected]… Media: Ashleigh Koss [email protected]
(1) Refer to Non-GAAP Financial Information section above for further disclosures on non-GAAP financial measures. A reconciliation between GAAP and non-GAAP financial information is provided in the tables below.
(in million… except percent… and per Three Nine share Months Months amounts) Ended Ended Non-GAAP September September adjustm… 30, 30, summary: 2026 2025 2026 2025 ────────────────────────────────────────────────────────────────────────────── Cost of goods $ 588 $ 577 $ 1,744 $ 1,735 sold adjustm… Research and develop… 16 12 369 93 expenses adjustm… IPR&D impairm… — — 1,750 190 adjustm… Selling, general and 102 5 590 49 adminis… expenses adjustm… Total non-GAAP adjustm… 706 594 4,453 2,067 to costs and expenses Other (income) expense, 164 -483 -321 -198 net, adjustm… Total non-GAAP adjustm… 870 112 4,132 1,868 before income taxes Income tax effect of -175 -79 -807 -396 non-GAAP adjustm… above Discrete and related 62 11 64 101 tax charges… Total non-GAAP adjustm… $ 757 $ 43 $ 3,389 $ 1,573 to net income
(2) Adjustments include integration expenses and contingent consideration fair value adjustments associated with Gilead’s recent acquisitions.
(3) Adjustments include donations of equity securities to the Gilead Foundation, a California nonprofit organization, during the first quarter of 2026.
(4) Represents discrete and related deferred tax charges or benefits primarily associated with acquisition-related adjustments and transfers of intangible assets from a foreign subsidiary to Ireland and the United States.
(in millions, except percentages and per Provided Updated May Updated Updated share February 10, 7, August 4, October amounts) 2026 2026 2026 29, 2026 ────────────────────────────────────────────────────────────────────────────── Projected product gross margin GAAP to non-GAAP reconcilia… GAAP projected product ~ 79.0% ~ 79.0% ~ 79.0% ~ 79.0% gross margin Acquisitio… ~ 8.0% ~ 8.0% ~ 8.0% ~ 8.0% expenses Non-GAAP projected product ~ 87.0% ~ 87.0% ~ 87.0% ~ 87.0% gross margin Projected operating income (loss) GAAP to non-GAAP reconcilia… GAAP projected $11,400 - $(1,000) - $(2,250) - $(3,150) - operating $11,900 $(500) $(1,850) $(2,750) income (loss) Acquisitio… IPR&D impairment, ~ 2,400 ~ 3,400 ~ 5,150 ~ 5,150 restructur… and other expenses Non-GAAP projected $13,800 - $2,400 - $2,900 - $2,000 - operating $14,300 $2,900 $3,300 $2,400 income Projected effective tax rate GAAP to non-GAAP reconcilia… GAAP projected ~ 21% ~ (150%) - ~ (80%) - ~ (50%) - effective (220%) (90%) (55%) tax rate Income tax effect of above non-GAAP adjustments and fair value adjustments -~ 1% NM NM NM of equity securities, and discrete and related tax adjustments Non-GAAP projected ~ 20% ~ 190% - ~ 140% - 115% ~ 220% - effective 140% 165% tax rate Projected diluted earnings (loss) per share GAAP to non-GAAP reconcilia… GAAP projected diluted $6.75 - $(3.25) - $(3.75) - $(4.40) - earnings $7.15 $(2.85) $(3.40) $(4.05) (loss) per share Acquisitio… IPR&D impairment, restructur… and other expenses, fair value ~ 1.70 ~ 2.20 ~ 3.10 ~ 3.20 adjustments of equity securities and discrete and related tax adjustments Non-GAAP projected diluted $8.45 - $(1.05) - $(0.65) - $(1.20) - earnings $8.85 $(0.65) $(0.30) $(0.85) (loss) per share
(1) Our full-year guidance excludes the potential impact of any (i) acquisitions or business development transactions that have not been executed, (ii) future fair value adjustments of equity securities and (iii) discrete tax charges or benefits associated with changes in tax related laws and guidelines that have not been enacted, as Gilead is unable to project such amounts. The non-GAAP full-year guidance includes non-GAAP adjustments to actual current period results as well as adjustments for the known future impact associated with events that have already occurred, such as future amortization of our intangible assets and the future impact of discrete and related deferred tax charges or benefits primarily associated with transfers of intangible assets from a foreign subsidiary to Ireland and the United States.
(2) The GAAP and non-GAAP projected effective tax rates for the October 29, 2026 update include the impact of Acquired IPR&D expenses related to the acquisitions of Arcellx, Tubulis and Ouro Medicines, which are not deductible for tax purposes. Without these Acquired IPR&D expenses, the GAAP and non-GAAP projected effective tax rate for FY26 would be ~21% and ~20%, respectively.
(1) Includes current and long-term inventories, which are disclosed separately in the notes to our financial statements in Form 10-K and Form 10-Q.
(2) As of September 30, 2026 and December 31, 2025, there were 1,241 of shares of common stock issued and outstanding.
(1) Free cash flow is a non-GAAP liquidity measure. Please refer to our disclosures in the Non-GAAP Financial Information section above.
(1) Represents Gilead’s revenue from cobicistat (“C”), FTC and TAF in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company.
(2) Includes Atripla, Bixlenvo, Complera/Eviplera, Emtriva, Stribild, Sunlenca, Truvada and Tybost.
(3) Includes Epclusa and the authorized generic version of Epclusa sold by Gilead’s separate subsidiary, Asegua Therapeutics LLC (“Asegua”).
(4) Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version of Harvoni sold by Asegua), Hepcludex, Sovaldi, Viread and Vosevi.
Full text with the tables
October 29, 2026 1
───────────────────────
GILEAD SCIENCES ANNOUNCES THIRD QUARTER 2026 FINANCIAL RESULTS
Product Sales Excluding Veklury Increased 16% Year-Over-Year to $8.2 Billion
Biktarvy Sales Increased 10% Year-Over-Year to $4.1 Billion
Foster City, CA, October 29, 2026
- Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations
for the third quarter 2026.
“Gilead delivered an exceptional third quarter, with our strongest year-over-
year base business growth in more than a decade, reflecting the strength,
breadth and durability of our business,” said Daniel O’Day, Gilead’s Chairman
and Chief Executive Officer. “Our performance enabled us to raise our full year
base business revenue guidance again this quarter, bringing the total increase
to $1.6 billion since the start of 2026. Our HIV business grew 18% and HIV
prevention sales nearly doubled year-over-year. With multiple ongoing and
potential launches across HIV and Oncology, important progress in Inflammation
and a disciplined operating model, Gilead is well positioned for business growth
and impact for patients.”
Third Quarter 2026 Financial Results
• Total third quarter 2026 product sales increased 13% to $8.3 billion compared
to the same period in 2025, primarily driven by higher sales of HIV products,
Trodelvy® (sacituzumab govitecan-hziy) and Livdelzi® (seladelpar), partially
offset by lower sales of Veklury® (remdesivir) and Cell Therapy products. Higher
product sales were partially offset by lower royalty, contract and other
revenues, primarily driven by revenues recognized in the prior year related to a
previous sale of intellectual property, which did not repeat in the current
year.
• Diluted earnings per share (“EPS”) was $1.94 in the third quarter 2026
compared to $2.43 in the same period in 2025. The decrease was primarily driven
by net losses from equity securities in the current year compared to net gains
in the prior year, higher operating expenses, higher income tax expense and
lower royalty, contract and other revenues, partially offset by higher product
sales and lower acquired in-process research and development (“IPR&D”) expenses.
• Non-GAAP diluted EPS was $2.55 in the third quarter 2026 compared to $2.47 in
the same period in 2025. The increase was primarily driven by higher product
sales and lower acquired IPR&D expenses, partially offset by higher operating
expenses, higher income tax expense and lower royalty, contract and other
revenues.
• As of September 30, 2026, Gilead had $6.4 billion of cash, cash equivalents
and marketable debt securities compared to $10.6 billion as of December 31,
2025. The decrease was primarily driven by year-to-date cash outflows of $11.3
billion related to acquisitions, $2.8 billion of debt repayments, $3.1 billion
of dividend payments and $1.1 billion of common stock repurchases, partially
offset by $11.2 billion of operating cash flow and $4.1 billion of net proceeds
from debt financing.
• During the third quarter 2026, Gilead generated $5.0 billion in operating cash
flow.
• During the third quarter 2026, Gilead paid dividends of $1.0 billion and
repurchased $370 million of common stock.
October 29, 2026 2
───────────────────────
Third Quarter 2026 Product Sales
As noted in the section above, total third quarter 2026 product sales increased
compared to the same period in 2025. Total third quarter 2026 product sales
excluding Veklury increased 16% to $8.2 billion compared to the same period in
2025, primarily due to higher sales of HIV products, Trodelvy and Livdelzi,
partially offset by lower sales of Cell Therapy products.
HIV
product sales increased 18% to $6.2 billion in the third quarter 2026 compared
to the same period in 2025, primarilydriven by higher average realized price,
higher demand in HIV prevention and favorable inventory dynamics.
•
Biktarvy®
(bictegravir 50mg/emtricitabine (“FTC”) 200mg/tenofovir alafenamide (“TAF”)
25mg) sales increased 10% to $4.1 billion in the third quarter 2026 compared to
the same period in 2025, primarily driven by higher demand, higher average
realized price and favorable inventory dynamics.
•
Descovy®
(FTC 200mg/TAF 25mg) sales increased 49% to $1.0 billion in the third quarter
2026 compared to the same period in 2025, primarily driven by higher average
realized price and favorable inventory dynamics.
The
Liver Disease
portfolio sales increased 13% to $927 million in the third quarter 2026 compared
to the same period in 2025, primarily reflecting higher demand for Livdelzi, as
well as higher average realized price for chronic hepatitis C virus (“HCV”) and
chronic hepatitis B virus products, partially offset by lower demand for HCV
products.
Veklury
sales decreased 69% to $86 million in the third quarter 2026 compared to the
same period in 2025, primarily driven by lower rates of COVID-19-related
hospitalizations.
Cell Therapy
product sales decreased 18% to $355 million in the third quarter 2026 compared
to the same period in 2025, reflecting ongoing competitive headwinds.
Trodelvy®
(sacituzumab govitecan-hziy) sales increased 42% to $506 million in the third
quarter 2026 compared to the same period in 2025, primarily driven by higher
demand.
Third Quarter 2026 Product Gross Margin, Operating Expenses and Effective Tax
Rate
• Product gross margin was 81.0% in the third quarter 2026 compared to 78.6% in
the same period in 2025. Non-GAAP product gross margin was 88.1% in the third
quarter 2026 compared to 86.5% in the same period in 2025. These increases were
primarily driven by the expiration of a royalty-related obligation.
• Research and development (“R&D”) expenses and non-GAAP R&D expenses increased
to $1.6 billion in the third quarter 2026 compared to $1.3 billion in the same
period in 2025, primarily driven by higher employee-related and clinical
materials costs.
• Acquired IPR&D expenses were $18 million in the third quarter 2026.
• Selling, general and administrative (“SG&A”) expenses increased to $1.6
billion in the third quarter 2026 compared to $1.4 billion in the same period in
2025, primarily driven by higher HIV promotional activities, integration costs
related to our recent acquisitions, higher expenses related to legal matters and
higher employee-related costs. Non-GAAP SG&A expenses increased to $1.5 billion
in the third quarter 2026 compared to $1.4 billion in the same period in 2025,
primarily due to higher HIV promotional activities, higher expenses related to
legal matters and higher employee-related costs.
• The effective tax rate (“ETR”) was 20.7% in the third quarter 2026 compared to
16.2% in the same period in 2025, primarily driven by a settlement with a tax
authority and remeasurement of certain deferred tax liabilities in the prior
year, which did not repeat in the current year. The non-GAAP ETR was 19.0% in
the third quarter 2026 compared to 17.5% in the same period in 2025, primarily
due to the settlement with a tax authority in the prior year.
October 29, 2026 3
───────────────────────
Guidance and Outlook
For the full year 2026, Gilead now expects:
(in Compa…
mill… to
exce… Octob… August
per 29, 4,
share Low 2026 High 2026
amou… End Guida… End Guida…
──────────────────────────────────────────────────────────────────────────────
Previ…
Prod… $ 31,000 $ 31,300 $30,1…
sales to
$30,4…
Prod… Previ…
sales $ 30,700 $ 31,000 $29,8…
excl… to
Vekl… $30,1…
Vekl… ~ $300 Uncha…
Dilu… Previ…
loss $ -4.40 $ -4.05 $(3.7…
per to
share $(3.4…
Non-… Previ…
dilu… $(0.6…
loss $ -1.20 $ -0.85 to
per $(0.3…
share
Our full year 2026 GAAP and non-GAAP diluted loss per share guidance includes
the impact of approximately $9.88 due to acquired IPR&D charges of $12.4 billion
related to the Arcellx, Tubulis, Ouro Medicines and PepStar transactions
announced this year, net of the impact of the Lakefront collaboration and
related taxes.
Additional information and a reconciliation between GAAP and non-GAAP financial
information for the 2026 guidance is provided in the accompanying tables. The
financial guidance is subject to a number of risks and uncertainties. See the
Forward-Looking Statements section below.
Key Updates Since Our Last Quarterly Release
Virology
• Received U.S. Food and Drug Administration (“FDA”) approval for Bixlenvo™
(bictegravir 75 mg/lenacapavir 50 mg) for the treatment of HIV in adults who are
virologically suppressed on a stable antiretroviral regimen, including those
switching from complex multi-tablet regimens. Bixlenvo is a complete single-
tablet regimen indicated for the treatment of HIV to replace current
antiretroviral regimens in people with virological suppression with no known or
suspected resistance to bictegravir or lenacapavir.
• Announced the expansion of the six royalty-free voluntary licensing agreements
for twice-yearly lenacapavir to include the investigational once-yearly
lenacapavir for HIV prevention, if approved. This agreement covers 120 high-
incidence countries and will support manufacturing readiness, technology
transfer and future supply while the Phase 3 PURPOSE-365 trial is ongoing. If
approved, once-yearly lenacapavir could provide a full year of HIV prevention
with a single annual dose, expanding prevention choice and helping address
barriers that can limit HIV pre-exposure prophylaxis (“PrEP”) uptake and
persistence.
• Announced a new agreement with the Pan American Health Organization (“PAHO”)
to accelerate access for twice-yearly lenacapavir for HIV prevention across all
PAHO Member States in Latin America and the Caribbean. This agreement is part of
Gilead’s broader global access strategy for lenacapavir which combines voluntary
licensing, technology transfer, no-profit supply, regional access pathways and
partnerships in providing access to HIV prevention.
Oncology
• Announced European Commission (“EC”) marketing authorization for Trodelvy in
combination with Keytruda® (pembrolizumab) for the treatment of adult patients
with unresectable locally advanced or metastatic triple-negative breast cancer
(“mTNBC”) who have not received prior systemic therapy for metastatic disease
and whose tumors express PD-L1 (CPS≥10). This decision follows the recent EC
approval of Trodelvy as a monotherapy for the treatment of adults with
unresectable locally advanced or mTNBC who have not received prior systemic
therapy for metastatic disease and are not candidates for PD-(L)1 inhibitors.
Trodelvy is now the only approved Trop-2 directed ADC and backbone therapy for
1L mTNBC across PD-L1 status.
October 29, 2026 4
───────────────────────
Inflammation
• Announced a definitive agreement with PepStar Therapeutics Limited
(“PepStar”), a privately held, clinical-stage biotechnology company, to acquire
PepStar’s oral IL-23R inhibitor program. This includes lead asset HCXT-2001, an
investigational, oral, macrocyclic peptide inhibitor of IL-23R, currently in
Phase 1 development for immune-mediated inflammatory diseases. Closing of the
transaction is subject to certain customary conditions.
• Presented new positive results from the Phase 2 SWIFT study evaluating
emvistegrast, a once-daily oral alpha-4-beta-7 inhibitor, in adults with
moderately-to-severely active ulcerative colitis (“UC”) at the United European
Gastroenterology Week. Emvistegrast 200mg met its primary endpoint of clinical
response at Week 12, with a generally well-tolerated safety profile. These
findings support Gilead’s plans to initiate a Phase 3 study of emvistegrast
200mg as a monotherapy for UC in 2027. Emvistegrast is an investigational
product that is not approved anywhere globally, and the safety and efficacy of
its use is not yet established.
Corporate
• Announced opening of new Research Center to expand capabilities in oncology,
inflammation and research data science. The Research Center is the first of
three projects supporting the $32 billion investment in U.S. research,
development and manufacturing through 2030.
• In October 2026, the Centers for Medicare and Medicaid Services completed the
process of setting the Maximum Fair Price for Biktarvy under Medicare. The new
price will be effective and impact our Biktarvy revenue starting January 1,
2028.
• The Board declared a quarterly dividend of $0.82 per share of common stock for
the fourth quarter of 2026. The dividend is payable on December 30, 2026, to
stockholders of record at the close of business on December 15, 2026. Future
dividends will be subject to Board approval.
Certain amounts and percentages in this press release may not sum or recalculate
due to rounding.
Conference Call
At 1:30 p.m. Pacific Time today, Gilead will host a conference call to discuss
Gilead’s results. A live webcast will be available on
http://investors.gilead.com and will be archived on www.gilead.com for one year.
Non-GAAP Financial Information
The information presented in this document has been prepared in accordance with
U.S. generally accepted accounting principles (“GAAP”), unless otherwise noted
as non-GAAP. Management believes non-GAAP information is useful for investors,
when considered in conjunction with Gilead’s GAAP financial information, because
management uses such information internally for its operating, budgeting and
financial planning purposes. Non-GAAP information is not prepared under a
comprehensive set of accounting rules and should only be used to supplement an
understanding of Gilead’s operating results as reported under GAAP. Non-GAAP
financial information generally excludes acquisition-related expenses including
amortization of acquired intangible assets, restructuring charges and other
items that are considered unusual or not representative of underlying trends of
Gilead’s business, fair value adjustments of equity securities, the related tax
charges or benefits associated with such exclusions and other discrete tax
charges or benefits not representative of underlying trends such as changes in
tax laws, transfers of intangible assets between certain legal entities, and
effects of legal entity restructurings. Although Gilead consistently excludes
the amortization of acquired intangible assets from the non-GAAP financial
information, management believes that it is important for investors to
understand that such intangible assets were recorded as part of acquisitions and
contribute to ongoing revenue generation. Non-GAAP measures may be defined and
calculated differently by other companies in the same industry. Reconciliations
of the non-GAAP financial measures to the most directly comparable GAAP
financial measures are provided in the accompanying tables.
October 29, 2026 5
───────────────────────
About Gilead Sciences
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and
achieved breakthroughs in medicine for more than three decades, with the goal of
creating a healthier world for all people. The company is committed to advancing
innovative medicines to prevent and treat life-threatening diseases, including
HIV, viral hepatitis, COVID-19, cancer and inflammation. Gilead operates in more
than 35 countries worldwide, with headquarters in Foster City, California.
Forward-Looking Statements
Statements included in this press release that are not historical in nature are
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. Gilead cautions readers that forward-looking
statements are subject to certain risks and uncertainties that could cause
actual results to differ materially. These risks and uncertainties include those
relating to: Gilead’s ability to achieve its full year 2026 financial guidance
and future projected financial results; impacts resulting from regulatory or
legislative policies or processes, including the impact from pricing reform in
the Inflation Reduction Act (such as Medicare Part D pricing reform and the
Biktarvy Maximum Fair Price determination), the expiration of subsidies related
to the Affordable Care Act, our most-favored-nation pricing agreement with the
U.S. government and tariffs; Gilead’s ability to make progress on any of its
long-term ambitions or priorities laid out in its corporate strategy; Gilead’s
ability to accelerate or sustain revenues for its virology, oncology,
inflammation and other programs; Gilead’s ability to manage, execute and realize
the potential benefits of acquisitions, collaborations or licensing
arrangements, including the announced PepStar acquisition; the risk that
Gilead’s U.S. manufacturing and R&D investment may not achieve their intended
benefits; patent protection and estimated loss of exclusivity for our products
and product candidates; Gilead’s ability to initiate, progress or complete
clinical trials within currently anticipated timeframes or at all, the
possibility of unfavorable results from ongoing and additional clinical trials,
including those involving anito-cel, emvistegrast, lenacapavir and HCXT-2001
(such as PURPOSE-365 and SWIFT), and the risk that safety and efficacy data from
clinical trials may not warrant further development of Gilead’s product
candidates or the product candidates of Gilead’s strategic partners; Gilead’s
ability to resolve the issues cited by the FDA in pending clinical holds to the
satisfaction of the FDA and the risk that FDA may not remove such clinical
holds, in whole or in part, in a timely manner or at all; Gilead’s ability to
submit new drug applications for new product candidates or expanded indications
in the currently anticipated timelines; Gilead’s ability to receive or maintain
regulatory approvals in a timely manner or at all, and the risk that any such
approvals, if granted, may be subject to significant limitations on use and may
be subject to withdrawal or other adverse actions by the applicable regulatory
authority; Gilead’s ability to successfully commercialize its products; the risk
of potential disruptions to the manufacturing and supply chain of Gilead’s
products; pricing and reimbursement pressures from government agencies and other
third parties, including required rebates and other discounts; a larger than
anticipated shift in payer mix to more highly discounted payer segments; market
share and price erosion caused by the introduction of generic versions of Gilead
products; the risk that physicians and patients may not see advantages of
Gilead’s products over other therapies, including Bixlenvo and Trodelvy;
Gilead’s ability to effectively manage, execute and realize the anticipated
benefits of the access strategy relating to lenacapavir for HIV PrEP, including
voluntary licensing arrangements and external partnerships relating to
lenacapavir; and other risks identified from time to time in Gilead’s reports
filed with the SEC, including annual reports on Form 10-K, quarterly reports on
Form 10-Q and current reports on Form 8-K. In addition, Gilead makes estimates
and judgments that affect the reported amounts of assets, liabilities, revenues
and expenses and related disclosures. Gilead bases its estimates on historical
experience and on various other market specific and other relevant assumptions
that it believes to be reasonable under the circumstances, the results of which
form the basis for making judgments about the carrying values of assets and
liabilities that are not readily apparent from other sources. There may be other
factors of which Gilead is not currently aware that may affect matters discussed
in the forward-looking statements and may also cause actual results to differ
significantly from these estimates. Further, results for the quarter ended
September 30, 2026 are not necessarily indicative of operating results for any
future periods. Gilead directs readers to its press releases, annual reports on
Form 10-K, quarterly reports on Form 10-Q and other subsequent disclosure
documents filed with the SEC. Gilead claims the protection of the Safe Harbor
contained in the Private Securities Litigation
October 29, 2026 6
───────────────────────
Reform Act of 1995 for forward-looking statements.
The reader is cautioned that forward-looking statements are not guarantees of
future performance and is cautioned not to place undue reliance on these
forward-looking statements. All forward-looking statements are based on
information currently available to Gilead and Gilead assumes no obligation to
update or supplement any such forward-looking statements other than as required
by law. Any forward-looking statements speak only as of the date hereof or as of
the dates indicated in the statements.
Additional information is available on our Investor Relations website,
https://investors.gilead.com. Among other things, an estimate of Acquired IPR&D
expenses is expected to be made available on the Quarterly Results page within
the first ten (10) days after the end of each quarter.
# # #
G ilead owns or has rights to various trademarks, copyrights and trade names
used in its business, including the following: GILEAD®, GILEAD SCIENCES®, KITE®,
AMBISOME®, ATRIPLA®, BIXLENVO ™ , BIKTARVY®, CAYSTON®, COMPLERA®, DESCOVY®,
DESCOVY FOR PREP®, EMTRIVA®, EPCLUSA®, EVIPLERA®, GENVOYA®, HARVONI®,
HEPCLUDEX®, JYSELECA®, LIVDELZI®/LYVDELZI®, LETAIRIS®, ODEFSEY®, SOVALDI®,
STRIBILD®, SUNLENCA®, TECARTUS®, TRODELVY®, TRUVADA®, TRUVADA FOR PREP®,
TYBOST®, VEKLURY®, VEMLIDY®, VIREAD®, VOSEVI®, YESCARTA®, YEZTUGO®/YEYTUO® and
ZYDELIG®. Other trademarks and trade names are the property of their respective
owners.
For more information on Gilead Sciences, Inc., please visit www.gilead.com or
call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).
CONTACTS: Investors: Jacquie Ross, CFA [email protected]…
Media: Ashleigh Koss [email protected]
October 29, 2026 7
───────────────────────
GILEAD SCIENCES, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(unaudited)
(in
mil… Three Nine
exc… Mont… Mon…
per Ended End…
sha… Sept… Sep…
amo… 30, 30,
Rev… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Pro… $ 8,289 $ 7,345 $ 22,8… $ 21,…
sal…
Roy…
con…
and 11 424 201 505
oth…
rev…
Tot… 8,300 7,769 23,0… 21,…
rev…
Cos…
and
exp…
Cost
of 1,571 1,569 4,595 4,6…
goo…
sold
Res…
and 1,608 1,346 4,744 4,2…
dev…
exp…
Acq…
in-…
res… 18 170 11,3… 485
and
dev…
exp…
In-…
res…
and — — 1,750 190
dev…
imp…
Sel…
gen…
and 1,641 1,357 5,013 3,9…
adm…
exp…
Tot…
cos… 4,838 4,442 27,4… 13,…
and
exp…
Ope…
inc… 3,462 3,327 -4,3… 8,0…
(lo…
Int… 269 256 756 769
exp…
Oth…
(in… 130 -569 -492 -449
exp…
net
Inc…
(lo…
bef… 3,063 3,641 -4,6… 7,7…
inc…
tax…
Inc…
tax 634 589 1,435 1,3…
exp…
Net
inc… $ 2,429 $ 3,052 $ -6,0… $ 6,3…
(lo…
Bas…
ear…
(lo… $ 1.96 $ 2.46 $ -4.87 $ 5.08
per
sha…
Dil…
ear…
(lo… $ 1.94 $ 2.43 $ -4.87 $ 5.04
per
sha…
Sha…
used
in
bas…
ear… 1,242 1,243 1,242 1,2…
(lo…
per
sha…
cal…
Sha…
used
in
dil…
ear… 1,251 1,254 1,242 1,2…
(lo…
per
sha…
cal…
Sup…
Inf…
Cash
div…
dec… $ 0.82 $ 0.79 $ 2.46 $ 2.37
per
sha…
Pro…
gro… 81.0 % 78.6 % 79.9 % 78.1 %
mar…
Res…
and
dev…
exp… 19.4 % 17.3 % 20.6 % 19.6 %
as a
%
of
rev…
Sel…
gen…
and
adm… 19.8 % 17.5 % 21.7 % 18.5 %
exp…
as a
% of
rev…
Ope… 41.7 % 42.8 % -18.8 % 37.4 %
mar…
Eff…
tax 20.7 % 16.2 % -31.1 % 18.0 %
rate
October 29, 2026 8
───────────────────────
GILEAD SCIENCES, INC.
TOTAL REVENUE SUMMARY
(unaudited)
(in Thr… Nine
mi… Mon… Mon…
ex… End… End…
pe… Sep… Sep…
Pr… 30, 30,
sa… 2026 2025 Cha… 2026 2025 Cha…
──────────────────────────────────────────────────────────────────────────────
HIV $ 6,2… $ 5,2… 18% $ 16,… $ 14,9… 14%
Li… 927 819 13% 2,5… 2,372 8%
Di…
On… 860 788 9% 2,5… 2,395 6%
Ot… 167 184 (9)% 524 594 (12…
To…
pr…
sa… 8,2… 7,0… 16% 22,… 20,3… 11%
ex…
Ve…
Ve… 86 277 (69… 253 700 (64…
To…
pr… 8,2… 7,3… 13% 22,… 21,0… 9%
sa…
Ro…
co…
and 11 424 (97… 201 505 (60…
ot…
re…
To… $ 8,3… $ 7,7… 7% $ 23,… $ 21,5… 7%
re…
October 29, 2026 9
───────────────────────
GILEAD SCIENCES, INC.
NON-GAAP FINANCIAL INFORMATION
(1)
(unaudited)
Th… Ni…
(… Mo… Mo…
m… En… En…
e… Se… Se…
p… 30, 30,
N… 20… 20… Ch… 20… 20… Ch…
──────────────────────────────────────────────────────────────────────────────
C…
of $ 983 $ 992 (1… $ 2,… $ 2,… (1…
g…
s…
R…
a… $ 1,… $ 1,… 19% $ 4,… $ 4,… 6%
d…
e…
A…
i…
r… $ 18 $ 170 (8… $ 11… $ 485 NM
a…
d…
e…
S…
g…
a… $ 1,… $ 1,… 14% $ 4,… $ 3,… 13%
a…
e…
O…
(… $ -34 $ -87 (6… $ -1… $ -2… (3…
e…
n…
D…
e…
(… $ 2.… $ 2.… 3% $ -2… $ 6.… NM
p…
s…
S…
u…
in
n…
d… 1,… 1,… —% 1,… 1,… (1…
e…
(…
p…
s…
c…
P… 165 121
g… 88… % 86… % bps 87… % 86… % bps
m…
R…
a…
d…
e… 200 (1…
as 19… % 17… % bps 19… % 19… % bps
a
%
of
r…
S…
g…
a…
a…
e… 18… % 17… % 115 19… % 18… % 91
as bps bps
a
%
of
r…
O… 50… % 50… % (2… 0.5 % 47… % NM
m… bps
E… 149
t… 19… % 17… % bps -4… % 17… % NM
r…
________________________________
NM - Not Meaningful
(1) Refer to Non-GAAP Financial Information section above for further
disclosures on non-GAAP financial measures. A reconciliation between GAAP and
non-GAAP financial information is provided in the tables below.
October 29, 2026 10
────────────────────────
GILEAD SCIENCES, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION
(unaudited)
(in
mil…
exc…
per…
and
per
sha…
amo… Three Nine
Cost Mont… Mon…
of Ended End…
goo… Sept… Sep…
sold 30, 30,
rec… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
GAAP
cost
of $ 1,571 $ 1,569 $ 4,595 $ 4,6…
goo…
sold
Acq…
– -587 -577 -1,7… -1,…
amo…
Res… -1 — -1 —
Non…
cost
of $ 983 $ 992 $ 2,851 $ 2,8…
goo…
sold
Pro…
gro…
mar…
rec…
GAAP
pro… 81.0 % 78.6 % 79.9 % 78.1 %
gro…
mar…
Acq…
– 7.1 % 7.9 % 7.6 % 8.3 %
amo…
Res… — % — % — % — %
Non…
pro… 88.1 % 86.5 % 87.5 % 86.3 %
gro…
mar…
Res…
and
dev…
exp…
rec…
GAAP
res…
and $ 1,608 $ 1,346 $ 4,744 $ 4,2…
dev…
exp…
Acq…
– -8 -4 -344 -41
oth…
cos…
Res… -8 -8 -25 -52
Non…
res…
and $ 1,591 $ 1,334 $ 4,375 $ 4,1…
dev…
exp…
IPR…
imp…
rec…
GAAP
IPR… $ — $ — $ 1,750 $ 190
imp…
IPR… — — -1,7… -190
imp…
Non…
IPR… $ — $ — $ — $ —
imp…
Sel…
gen…
and
adm…
exp…
rec…
GAAP
sel…
gen… $ 1,641 $ 1,357 $ 5,013 $ 3,9…
and
adm…
exp…
Acq…
– -69 — -454 —
oth…
cos…
Res… -33 -5 -73 -49
Oth… — — -63 —
Non…
sel…
gen… $ 1,539 $ 1,351 $ 4,423 $ 3,9…
and
adm…
exp…
Ope…
inc…
(lo…
rec…
GAAP
ope… $ 3,462 $ 3,327 $ -4,3… $ 8,0…
inc…
(lo…
Acq…
– 587 577 1,742 1,7…
amo…
Acq…
– 77 4 798 41
oth…
cos…
Res… 42 14 99 101
IPR… — — 1,750 190
imp…
Oth… — — 63 —
Non…
ope… $ 4,168 $ 3,921 $ 107 $ 10,…
inc…
Ope…
mar…
rec…
GAAP
ope… 41.7 % 42.8 % -18.8 % 37.4 %
mar…
Acq…
– 7.1 % 7.4 % 7.6 % 8.1 %
amo…
Acq…
– 0.9 % — % 3.5 % 0.2 %
oth…
cos…
Res… 0.5 % 0.2 % 0.4 % 0.5 %
IPR… — % — % 7.6 % 0.9 %
imp…
Oth… — % — % 0.3 % — %
Non…
ope… 50.2 % 50.5 % 0.5 % 47.0 %
mar…
Oth…
(in…
exp…
net
rec…
GAAP
oth…
(in… $ 130 $ -569 $ -492 $ -449
exp…
net
(Lo…
gain
from -164 483 321 198
equ…
sec…
net
Non…
oth…
(in… $ -34 $ -87 $ -171 $ -251
exp…
net
October 29, 2026 11
────────────────────────
GILEAD SCIENCES, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued)
(unaudited)
(in
mil…
exc…
per…
and
per
sha…
amo…
Inc… Three Nine
(lo… Mont… Mon…
bef… Ended End…
inc… Sept… Sep…
tax… 30, 30,
rec… 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
GAAP
inc…
(lo… $ 3,063 $ 3,641 $ -4,6… $ 7,7…
bef…
inc…
tax…
Acq…
– 587 577 1,742 1,7…
amo…
Acq…
– 77 4 798 41
oth…
cos…
Res… 42 14 99 101
IPR… — — 1,750 190
imp…
Loss
(ga…
from 164 -483 -321 -198
equ…
sec…
net
Oth… — — 63 —
Non…
inc…
(lo… $ 3,933 $ 3,752 $ -479 $ 9,5…
bef…
inc…
tax…
Inc…
tax
exp…
rec…
GAAP
inc… $ 634 $ 589 $ 1,435 $ 1,3…
tax
exp…
Inc…
tax
eff…
of
non…
adj…
Acq…
– 121 120 357 360
amo…
Acq…
– 16 — 95 —
oth…
cos…
Res… 9 3 18 18
IPR… — — 415 51
imp…
Loss
(ga…
from 30 -43 -78 -33
equ…
sec…
net
Dis…
and
rel… -62 -11 -64 -101
tax
cha…
Non…
inc… $ 747 $ 657 $ 2,177 $ 1,6…
tax
exp…
Eff…
tax
rate
rec…
GAAP
eff… 20.7 % 16.2 % -31.1 % 18.0 %
tax
rate
Inc…
tax
eff…
of
abo…
non…
adj… -1.7 % 1.3 % -423… % -0.4 %
and
dis…
and
rel…
tax
adj…
Non…
eff… 19.0 % 17.5 % -455… % 17.6 %
tax
rate
Net
inc…
(lo…
rec…
GAAP
net $ 2,429 $ 3,052 $ -6,0… $ 6,3…
inc…
(lo…
Acq…
– 467 457 1,385 1,3…
amo…
Acq…
– 61 4 703 41
oth…
cos…
Res… 33 11 81 83
IPR… — — 1,335 139
imp…
Loss
(ga…
from 134 -440 -243 -165
equ…
sec…
net
Dis…
and
rel… 62 11 64 101
tax
cha…
Oth… — — 63 —
Non…
net $ 3,186 $ 3,095 $ -2,6… $ 7,9…
inc…
(lo…
Dil…
ear…
(lo…
per
sha…
rec…
GAAP
dil…
ear… $ 1.94 $ 2.43 $ -4.87 $ 5.04
(lo…
per
sha…
Acq…
– 0.37 0.36 1.11 1.09
amo…
Acq…
– 0.05 — 0.57 0.03
oth…
cos…
Res… 0.03 0.01 0.07 0.07
IPR… — — 1.07 0.11
imp…
Loss
(ga…
from 0.11 -0.35 -0.20 -0.…
equ…
sec…
net
Dis…
and
rel… 0.05 0.01 0.05 0.08
tax
cha…
Oth… — — 0.05 —
Non…
dil…
ear… $ 2.55 $ 2.47 $ -2.14 $ 6.29
(lo…
per
sha…
October 29, 2026 12
────────────────────────
GILEAD SCIENCES, INC.
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL INFORMATION - (Continued)
(unaudited)
(in
million…
except
percent…
and per Three Nine
share Months Months
amounts) Ended Ended
Non-GAAP September September
adjustm… 30, 30,
summary: 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Cost of
goods $ 588 $ 577 $ 1,744 $ 1,735
sold
adjustm…
Research
and
develop… 16 12 369 93
expenses
adjustm…
IPR&D
impairm… — — 1,750 190
adjustm…
Selling,
general
and 102 5 590 49
adminis…
expenses
adjustm…
Total
non-GAAP
adjustm… 706 594 4,453 2,067
to costs
and
expenses
Other
(income)
expense, 164 -483 -321 -198
net,
adjustm…
Total
non-GAAP
adjustm… 870 112 4,132 1,868
before
income
taxes
Income
tax
effect
of -175 -79 -807 -396
non-GAAP
adjustm…
above
Discrete
and
related 62 11 64 101
tax
charges…
Total
non-GAAP
adjustm… $ 757 $ 43 $ 3,389 $ 1,573
to net
income
________________________________
(1) Relates to amortization of acquired intangibles.
(2) Adjustments include integration expenses and contingent consideration fair
value adjustments associated with Gilead’s recent acquisitions.
(3) Adjustments include donations of equity securities to the Gilead Foundation,
a California nonprofit organization, during the first quarter of 2026.
(4) Represents discrete and related deferred tax charges or benefits primarily
associated with acquisition-related adjustments and transfers of intangible
assets from a foreign subsidiary to Ireland and the United States.
October 29, 2026 13
────────────────────────
GILEAD SCIENCES, INC.
RECONCILIATION OF GAAP TO NON-GAAP 2026 FULL-YEAR GUIDANCE (1)
(unaudited)
(in
millions,
except
percentages
and per Provided Updated May Updated Updated
share February 10, 7, August 4, October
amounts) 2026 2026 2026 29, 2026
──────────────────────────────────────────────────────────────────────────────
Projected
product
gross
margin GAAP
to
non-GAAP
reconcilia…
GAAP
projected
product ~ 79.0% ~ 79.0% ~ 79.0% ~ 79.0%
gross
margin
Acquisitio… ~ 8.0% ~ 8.0% ~ 8.0% ~ 8.0%
expenses
Non-GAAP
projected
product ~ 87.0% ~ 87.0% ~ 87.0% ~ 87.0%
gross
margin
Projected
operating
income
(loss) GAAP
to non-GAAP
reconcilia…
GAAP
projected $11,400 - $(1,000) - $(2,250) - $(3,150) -
operating $11,900 $(500) $(1,850) $(2,750)
income
(loss)
Acquisitio…
IPR&D
impairment, ~ 2,400 ~ 3,400 ~ 5,150 ~ 5,150
restructur…
and other
expenses
Non-GAAP
projected $13,800 - $2,400 - $2,900 - $2,000 -
operating $14,300 $2,900 $3,300 $2,400
income
Projected
effective
tax rate
GAAP to
non-GAAP
reconcilia…
GAAP
projected ~ 21% ~ (150%) - ~ (80%) - ~ (50%) -
effective (220%) (90%) (55%)
tax rate
Income tax
effect of
above
non-GAAP
adjustments
and fair
value
adjustments -~ 1% NM NM NM
of equity
securities,
and
discrete
and
related tax
adjustments
Non-GAAP
projected ~ 20% ~ 190% - ~ 140% - 115% ~ 220% -
effective 140% 165%
tax rate
Projected
diluted
earnings
(loss) per
share GAAP
to non-GAAP
reconcilia…
GAAP
projected
diluted $6.75 - $(3.25) - $(3.75) - $(4.40) -
earnings $7.15 $(2.85) $(3.40) $(4.05)
(loss)
per share
Acquisitio…
IPR&D
impairment,
restructur…
and other
expenses,
fair
value ~ 1.70 ~ 2.20 ~ 3.10 ~ 3.20
adjustments
of equity
securities
and
discrete
and related
tax
adjustments
Non-GAAP
projected
diluted $8.45 - $(1.05) - $(0.65) - $(1.20) -
earnings $8.85 $(0.65) $(0.30) $(0.85)
(loss) per
share
________________________________
NM - Not Meaningful
(1) Our full-year guidance excludes the potential impact of any (i) acquisitions
or business development transactions that have not been executed, (ii) future
fair value adjustments of equity securities and (iii) discrete tax charges or
benefits associated with changes in tax related laws and guidelines that have
not been enacted, as Gilead is unable to project such amounts. The non-GAAP
full-year guidance includes non-GAAP adjustments to actual current period
results as well as adjustments for the known future impact associated with
events that have already occurred, such as future amortization of our intangible
assets and the future impact of discrete and related deferred tax charges or
benefits primarily associated with transfers of intangible assets from a foreign
subsidiary to Ireland and the United States.
(2) The GAAP and non-GAAP projected effective tax rates for the October 29, 2026
update include the impact of Acquired IPR&D expenses related to the acquisitions
of Arcellx, Tubulis and Ouro Medicines, which are not deductible for tax
purposes. Without these Acquired IPR&D expenses, the GAAP and non-GAAP projected
effective tax rate for FY26 would be ~21% and ~20%, respectively.
October 29, 2026 14
────────────────────────
GILEAD SCIENCES, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(unaudited)
(in millions) September 30, December 31,
Assets 2026 2025
──────────────────────────────────────────────────────────────────────────────
Cash, cash equivalents and
marketable $ 6,437 $ 10,605
debt securities
Accounts receivable, net 5,007 4,913
Inventories(1) 4,424 4,368
Property, plant and 5,945 5,606
equipment, net
Intangible assets, net 13,424 16,978
Goodwill 8,314 8,314
Other assets 7,858 8,239
Total assets $ 51,408 $ 59,023
Liabilities and
Stockholders’ Equity
Current liabilities $ 12,002 $ 11,813
Long-term liabilities 26,451 24,592
Stockholders’ equity(2) 12,955 22,618
Total liabilities and
stockholders’ $ 51,408 $ 59,023
equity
________________________________
(1) Includes current and long-term inventories, which are disclosed separately
in the notes to our financial statements in Form 10-K and Form 10-Q.
(2) As of September 30, 2026 and December 31, 2025, there were 1,241 of shares
of common stock issued and outstanding.
October 29, 2026 15
────────────────────────
GILEAD SCIENCES, INC.
SELECTED CASH FLOW INFORMATION
(unaudited)
Three Nine
Months Months
(in Ended Septe… Ended Septe…
milli… 2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net
cash
provi… $ 5,035 $ 4,109 $ 11,152 $ 6,692
by
opera…
activ…
Net
cash
used -244 -427 -8,821 -2,958
in
inves…
activ…
Net
cash
used -1,528 -1,490 -3,423 -6,482
in
finan…
activ…
Effect
of
excha…
rate
chang… -4 -5 -34 87
on
cash
and
cash
equiv…
Net
change
in
cash 3,259 2,187 -1,126 -2,661
and
cash
equiv…
Cash
and
cash
equiv… 3,179 5,144 7,564 9,991
at
begin…
of
period
Cash
and
cash
equiv… $ 6,437 $ 7,330 $ 6,437 $ 7,330
at end
of
period
Three Nine
Months Months
(in Ended Septem… Ended Septem…
milli… 2026 30, 2025 2026 30, 2025
──────────────────────────────────────────────────────────────────────────────
Net
cash
provi… $ 5,035 $ 4,109 $ 11,152 $ 6,692
by
opera…
activ…
Purch…
of
prope… -237 -147 -494 -358
plant
and
equip…
Free
cash $ 4,798 $ 3,962 $ 10,657 $ 6,335
flow(…
________________________________
(1) Free cash flow is a non-GAAP liquidity measure. Please refer to our
disclosures in the Non-GAAP Financial Information section above.
October 29, 2026 16
────────────────────────
GILEAD SCIENCES, INC.
PRODUCT SALES SUMMARY
(unaudited)
Three Nine
Mont… Mont…
Ended Ended
(in Sept… Sept…
mil… 30, 30,
HIV 2026 2025 2026 2025
──────────────────────────────────────────────────────────────────────────────
Bik… U.S. $ 3,284 $ 2,940 $ 8,837 $ 8,212
Euro… 442 427 1,347 1,231
Rest
of 333 320 1,009 922
World
4,059 3,686 11,193 10,3…
Des… U.S. 998 652 2,680 1,791
Euro… 22 23 69 67
Rest
of 26 25 71 81
World
1,046 701 2,820 1,939
Gen… U.S. 301 323 752 950
Euro… 27 34 97 114
Rest
of 12 19 44 54
World
339 377 892 1,118
Ode… U.S. 226 206 550 642
Euro… 52 61 170 184
Rest
of 8 10 27 30
World
286 277 747 857
Sym…
- U.S. 103 95 315 265
Rev…
sha…
Euro… 26 26 85 88
Rest
of 3 3 8 9
World
132 124 407 362
Yez… U.S. 294 39 676 54
Euro… — — — —
Rest
of 10 — 26 —
World
305 39 702 54
Oth… U.S. 55 43 114 144
HIV…
Euro… 22 22 72 85
Rest
of 5 8 24 28
World
82 73 211 256
Tot… U.S. 5,261 4,299 13,924 12,0…
HIV
Euro… 591 592 1,839 1,769
Rest
of 397 386 1,209 1,124
World
6,249 5,277 16,972 14,9…
October 29, 2026 17
────────────────────────
GILEAD SCIENCES, INC.
PRODUCT SALES SUMMARY - (Continued)
(unaudited)
Three Nine
Months Months
Ended Ended
Septem… Septe…
30, 30,
(in 2026 2025 2026 2025
mill…
Liver
Dise…
Livd… U.S. 176 93 437 207
Europe 26 11 65 16
Rest
of 1 — 1 —
World
203 105 503 223
Sofo…
/ U.S. 139 146 422 497
Velp…
Europe 59 65 200 227
Rest
of 76 97 237 273
World
274 309 860 996
Veml… U.S. 170 136 385 358
Europe 13 12 40 36
Rest
of 151 132 435 389
World
333 280 860 783
Other
Liver U.S. 39 39 74 100
Dise…
Europe 62 70 219 218
Rest
of 16 17 56 52
World
117 126 349 370
Total
Liver U.S. 524 414 1,319 1,162
Dise…
Europe 161 158 523 496
Rest
of 243 247 729 714
World
927 819 2,571 2,372
Vekl…
Vekl… U.S. 63 140 188 390
Europe 12 43 28 84
Rest
of 11 93 36 225
World
86 277 253 700
Onco…
Cell
Ther…
Teca… U.S. 24 40 83 122
Europe 31 35 102 107
Rest
of 5 8 21 25
World
60 83 206 254
Yesc… U.S. 114 123 366 444
Europe 107 151 392 455
Rest
of 73 75 215 228
World
294 349 973 1,127
Total
Cell U.S. 139 163 450 566
Ther…
Europe 138 186 494 562
Rest
of 78 83 235 253
World
355 432 1,179 1,381
Trod…
Trod… U.S. 336 221 896 626
Europe 98 89 285 259
Rest
of 71 47 183 128
World
506 357 1,364 1,013
Total U.S. 475 384 1,346 1,192
Onco…
Europe 236 275 779 821
Rest
of 149 129 418 381
World
860 788 2,543 2,395
October 29, 2026 18
────────────────────────
GILEAD SCIENCES, INC.
PRODUCT SALES SUMMARY - (Continued)
(unaudited)
Three Nine
Mont… Mont…
Ended Ended
Sept… Sept…
30, 30,
(in 2026 2025 2026 2025
mil…
Oth…
AmB… U.S. 3 2 14 15
Euro… 52 69 158 201
Rest
of 44 52 175 175
World
99 123 347 391
Oth… U.S. 36 34 97 125
Euro… 8 7 24 23
Rest
of 25 20 57 55
World
68 61 177 204
Tot… U.S. 39 36 111 140
Oth…
Euro… 59 76 181 225
Rest
of 69 72 232 230
World
167 184 524 594
Tot…
pro… U.S. 6,361 5,274 16,888 14,9…
sal…
Euro… 1,058 1,144 3,350 3,395
Rest
of 869 928 2,624 2,674
World
$ 8,289 $ 7,345 $ 22,862 $ 21,0…
________________________________
(1) Represents Gilead’s revenue from cobicistat (“C”), FTC and TAF in Symtuza
(darunavir/C/FTC/TAF), a fixed dose combination product commercialized by
Janssen Sciences Ireland Unlimited Company.
(2) Includes Atripla, Bixlenvo, Complera/Eviplera, Emtriva, Stribild, Sunlenca,
Truvada and Tybost.
(3) Includes Epclusa and the authorized generic version of Epclusa sold by
Gilead’s separate subsidiary, Asegua Therapeutics LLC (“Asegua”).
(4) Includes ledipasvir/sofosbuvir (Harvoni and the authorized generic version
of Harvoni sold by Asegua), Hepcludex, Sovaldi, Viread and Vosevi.
(5) Includes Cayston, Jyseleca, Letairis and Zydelig.